For its first fiscal quarter (ending March 31), Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has reported E.P.S. of $0.47 compared to $0.27 a year ago. E.P.S. were $1.09 for the latest four quarters through March 31 versus $0.38 for the same period a year ago.
Recent Price Action
On 4/24/24, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) stock declined slightly by -0.9%, closing at $91.20. Trading volume in this decline was normal. The stock is unchanged during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, BMRN is expected to continue to be an important Value Builder.
Biomarin Pharmaceutical has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Biomarin Pharmaceutical has a slightly negative Power Rating of 36 and a slightly negative Appreciation Score of 33, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment